CoChat

Renin‐angiotensin system and fibrosis in non‐alcoholic fatty liver disease

Goh, George B, Pagadala, Mangesh R, Dasarathy, Jaividhya, Unalp‐Arida, Aynur, Sargent, Ruth, Hawkins, Carol, Sourianarayanane, Achuthan, Khiyami, Amer, Yerian, Lisa, Pai, Rish, McCullough, Arthur J, Dasarathy, Srinivasan · 2015 · Liver International
Cited by 113

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Background & Aims: Therapeutic options are limited for patients with non‐alcoholic fatty liver disease (NAFLD). One promising approach is the attenuation of necroinflammation and fibrosis by inhibition of the renin‐angiotensin system (RAS). We explored whether the risk of fibrosis was associated with the use of commonly used medications in NAFLD patients with hypertension. Specifically, we sought to determine the association between RAS blocking agents and severity of hepatic fibrosis in NAFLD patients with hypertension. Methods: Cross‐sectional study where clinical information including demographics, anthropometry, medical history, concomitant medication use, biochemical and histological features were ascertained in 290 hypertensive patients with biopsy proven NAFLD followed at two hepatology outpatient clinics. Stage of hepatic fibrosis was compared in patients with and without RAS blocker use. Other risk factors for fibrosis were evaluated from the electronic medical records and patient follow‐up. Results: Baseline characteristics of hypertensive patients treated with and without RAS blockers were similar except for less ballooning (1.02 vs. 1.31, P = 0.001) and lower fibrosis stage (1.63 vs. 2.16, P = 0.002) in patients on RAS blockers On multivariate analysis, advancing age (OR: 1.04; 95%CI: 1.01–1.06, P = 0.012) and presence of diabetes (OR: 2.55; 95%CI: 1.28–5.09, P = 0.008) had an independent positive association, while use of RAS blockers (OR: 0.37; 95%CI: 0.21–0.65, P = 0.001) and statins (OR: 0.52; 95%CI: 0.29–0.93, P = 0.029) had a negative association with advanced fibrosis. Conclusion: Hypertensive patients with NAFLD on baseline RAS blockers had less advanced hepatic fibrosis suggesting a beneficial effect of RAS blockers in NAFLD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/liv.12611

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 113

Metadata

Authors
Goh, G. B., Pagadala, M. R., Dasarathy, J., Unalp‐Arida, A., Sargent, R., Hawkins, C., Sourianarayanane, A., Khiyami, A., Yerian, L., Pai, R., McCullough, A. J., & Dasarathy, S.
Venue
Liver International
Publisher
Wiley
Published
2014-07-05
Volume
35
Issue
3
Pages
979-985
ISSN
  • 0106-9543 (ISSN-L)
  • 1478-3223
  • 1478-3231
OpenAlex
W2161096403
Cited by
113
References
4
FWCI
6.97
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Renin‐angiotensin system and fibrosis in non‐alcoholic fatty liver disease. https://app.cochat.ai/papers/10.1111/liv.12611
The paper
Goh, G. B., Pagadala, M. R., Dasarathy, J., Unalp‐Arida, A., Sargent, R., Hawkins, C., Sourianarayanane, A., Khiyami, A., Yerian, L., Pai, R., McCullough, A. J., & Dasarathy, S. (2015). Renin‐angiotensin system and fibrosis in non‐alcoholic fatty liver disease. Liver International. https://doi.org/10.1111/liv.12611

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.